This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
by Zacks Equity Research
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Astrazeneca (AZN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
by Zacks Equity Research
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
by Kinjel Shah
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
by Zacks Equity Research
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
by Zacks Equity Research
AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More
by Kinjel Shah
EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
by Ekta Bagri
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $64.90, representing a -1.35% change from its previous close.
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
by Kinjel Shah
FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
by Zacks Equity Research
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
by Zacks Equity Research
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
by Zacks Equity Research
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
by Zacks Equity Research
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
by Kinjel Shah
Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.